Earnings call transcript: Unifique Telecomunicacoes Q4 2025 revenue beats forecasts

TL;DR

Earnings call transcript: Soul Patts reports strong H1 2026 results Earnings call transcript: ACG’s Q4 2025 shows revenue decline, market steady Earnings call transcript: Fleury SA Q4 2025 sees mixed market reaction Earnings call transcript: Methanex Q4 2025 misses expectations, stock dips Earnings call transcript: Compass Q4 2025 sees record revenue, stock up 2.5% Earnings call transcript: StandardAero Q4 2025 reports record revenue growth Earnings call transcript: California Resources Q4 2025 results reveal revenue surprise, EPS miss Earnings call transcript: Cryoport Q4 2025 misses EPS, stock rises on revenue beat Earnings call transcript: Syndax Pharmaceuticals Q4 2025 revenue beats forecast, stock rises Earnings call transcript: FIGR misses Q4 2025 EPS forecast, stock drops 27% Earnings call transcript: Inovio Q4 2025 earnings miss, stock dips Earnings call transcript: DEME’s Q4 2025 earnings surpass expectations Earnings call transcript: THG Holdings sees stock rise after H2 2025 recovery 2025 was “transformational” after the Ingenuity demerger as THG refocused on consumer brands; full‑year revenue rose 2.3% with a Beauty‑led rebound (Lookfantastic saw a 16.2% cyber sales uplift, app sales now 29% of revenue and strong creator/TikTok traction). Nutrition returned to growth (6.4%) but margins were pressured by record‑high whey prices and a weak yen, prompting a shift toward partnership/licensing (43m licensed products sold in 2025; >60m targeted in 2026) and expectations of more whey capacity in H2 2026. Balance sheet and margin actions: THG refinanced debt to 2029 and ended the year with GBP 333m liquidity, while deliberate portfolio/territory cuts and lifecycle investment created a c.560bp near‑term headwind now largely annualized; a pending HMRC VAT claim could deliver >GBP60m if successful.